These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10659750)

  • 21. Influence of timing on the dosimetric analysis of transperineal ultrasound-guided, prostatic conformal brachytherapy.
    Merrick GS; Butler WM; Dorsey AT; Walbert HL
    Radiat Oncol Investig; 1998; 6(4):182-90. PubMed ID: 9727878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Technique of intraoperative planning in prostatic brachytherapy with permanent implants of 125I or 103Pd].
    Prada Gómez PJ; Juan Rijo G; Hevia Suarez M; Abascal García JM; Abascal García R
    Arch Esp Urol; 2002 Dec; 55(10):1217-23; discussion 1223-4. PubMed ID: 12611219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monte Carlo calculated TG-43 dosimetry parameters for the SeedLink 125Iodine brachytherapy system.
    Medich DC; Munro JJ
    Med Phys; 2003 Sep; 30(9):2503-8. PubMed ID: 14528972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thermoluminescent dosimetry of the selectseed 125I interstitial brachytherapy seed.
    Anagnostopoulos G; Baltas D; Karaiskos P; Sandilos P; Papagiannis P; Sakelliou L
    Med Phys; 2002 May; 29(5):709-16. PubMed ID: 12033566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case-control study of permanent prostate brachytherapy patients.
    Butler WM; Stewart RR; Merrick GS
    Med Phys; 2009 Mar; 36(3):776-87. PubMed ID: 19378738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dosimetric characteristics of the InterSource103 palladium brachytherapy source.
    Meigooni AS; Sowards K; Soldano M
    Med Phys; 2000 May; 27(5):1093-100. PubMed ID: 10841414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of brachytherapy in the definitive management of prostate cancer.
    Crook J
    Cancer Radiother; 2011 Jun; 15(3):230-7. PubMed ID: 21514199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose effects of seeds placement deviations from pre-planned positions in ultrasound guided prostate implants.
    Dawson JE; Wu T; Roy T; Gu JY; Kim H
    Radiother Oncol; 1994 Sep; 32(3):268-70. PubMed ID: 7816946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of seed anisotrophy on brachytherapy dose distributions using 125I and 103Pd.
    Lindsay P; Battista J; Van Dyk J
    Med Phys; 2001 Mar; 28(3):336-45. PubMed ID: 11318315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A greedy heuristic using adjoint functions for the optimization of seed and needle configurations in prostate seed implant.
    Yoo S; Kowalok ME; Thomadsen BR; Henderson DL
    Phys Med Biol; 2007 Feb; 52(3):815-28. PubMed ID: 17228123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy.
    Stone NN; Hong S; Lo YC; Howard V; Stock RG
    Brachytherapy; 2003; 2(1):17-25. PubMed ID: 15062159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anisotropy functions for 103Pd, 125I, and 192Ir interstitial brachytherapy sources.
    Nath R; Meigooni AS; Muench P; Melillo A
    Med Phys; 1993; 20(5):1465-73. PubMed ID: 8289730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of source batch S dispersion on dosimetry for prostate cancer treatment with permanent implants.
    Nuñez-Cumplido E; Perez-Calatayud J; Casares-Magaz O; Hernandez-Armas J
    Med Phys; 2015 Aug; 42(8):4933-40. PubMed ID: 26233219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of edema on planning 125I and 103Pd prostate implants.
    Yue N; Dicker AP; Nath R; Waterman FM
    Med Phys; 1999 May; 26(5):763-7. PubMed ID: 10360539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
    Dicker AP; Lin CC; Leeper DB; Waterman FM
    Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dosimetric effects of edema in permanent prostate seed implants: a rigorous solution.
    Chen Z; Yue N; Wang X; Roberts KB; Peschel R; Nath R
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1405-19. PubMed ID: 10889396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moving toward focal therapy in prostate cancer: dual-isotope permanent seed implants as a possible solution.
    Todor DA; Barani IJ; Lin PS; Anscher MS
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):297-304. PubMed ID: 21536392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era?
    Kudchadker RJ; Swanson DA; Kuban DA; Lee AK; Bruno TL; Frank SJ
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):623-7. PubMed ID: 18410998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of urinary catheterization on dosimetry after prostate implant brachytherapy with palladium-103 or iodine-125.
    Shirvani SM; Kudchadker RJ; Bruno TL; Likhacheva A; Swanson DA; Frank SJ
    Brachytherapy; 2011; 10(4):269-74. PubMed ID: 21296031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement of transperineal implant dosimetry by intraoperative cystoscopic confirmation of prostate anatomy.
    Baird MC; Holt RW; Selby TL
    J Urol; 2000 Aug; 164(2):406-10. PubMed ID: 10893597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.